Open this publication in new window or tab >>Center for Haematology and Regenerative Medicine, Department of Medicine Huddinge, Karolinska Institutet, Huddinge, Sweden.
Science for Life Laboratory (SciLifeLab), Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden.
Science for Life Laboratory (SciLifeLab), Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden.
Science for Life Laboratory (SciLifeLab), Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden; Instituto de Biomedicina de Sevilla (IBiS), Hospital Universitario Virgen del Rocío, CSIC, Universidad de Sevilla, Sevilla, Spain; Departamento de Biología Celular, Facultad de Biología, Universidad de Sevilla, Sevilla, Spain.
Center for Haematology and Regenerative Medicine, Department of Medicine Huddinge, Karolinska Institutet, Huddinge, Sweden; Department of Medicine, Division of Hematology, Karolinska University Hospital, Huddinge, Sweden.
Center for Haematology and Regenerative Medicine, Department of Medicine Huddinge, Karolinska Institutet, Huddinge, Sweden; Department of Medicine, Division of Hematology, Karolinska University Hospital, Huddinge, Sweden.
Department of Medicine, Division of Hematology, Karolinska University Hospital, Huddinge, Sweden; Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden; Hematology Unit, Department of Medical Sciences, Uppsala University, Uppsala, Sweden.
Umeå University, Faculty of Medicine, Department of Medical Biochemistry and Biophysics.
Center for Haematology and Regenerative Medicine, Department of Medicine Huddinge, Karolinska Institutet, Huddinge, Sweden; Department of Medicine, Division of Hematology, Karolinska University Hospital, Huddinge, Sweden.
Center for Haematology and Regenerative Medicine, Department of Medicine Huddinge, Karolinska Institutet, Huddinge, Sweden.
Science for Life Laboratory (SciLifeLab), Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden.
Division of Paediatric Oncology and Surgery, Department of Women’s and Children’s Health, Karolinska Institutet, Stockholm, Sweden.
Division of Paediatric Oncology and Surgery, Department of Women’s and Children’s Health, Karolinska Institutet, Stockholm, Sweden; Paediatric Oncology, Astrid Lindgren Children’s Hospital, Karolinska University Hospital, Stockholm, Sweden.
Show others...
2025 (English)In: Cell Cycle, ISSN 1538-4101, E-ISSN 1551-4005Article in journal (Refereed) Epub ahead of print
Abstract [en]
Cytarabine (ara-C) and fludarabine (F-ara-A) are key drugs in leukaemia treatment. SAMHD1 is known to confer resistance to ara-C and F-ara-A, and we previously identified ribonucleotide reductase inhibitors as indirect SAMHD1 inhibitors in a phenotypic screen. The inosine monophosphate dehydrogenase (IMPDH) inhibitor mycophenolic acid (MPA) was also a hit in this screen. IMPDH inhibitors (IMPDHi) have previously shown efficacy against KMT2A-rearranged (KMT2Ar) acute myeloid leukaemia (AML). We investigated whether IMPDH inhibition could enhance the effect of ara-C and F-ara-A in AML cell lines and primary AML samples, and whether this effect was linked to KMT2A status. We found that sensitivity to IMPDHi was independent of KMT2A status. IMPDHi synergized with ara-C and F-ara-A in a SAMHD1-dependent manner in a subset of AML cells, but not in acute lymphoblastic leukaemia cell lines. Mechanistically, IMPDHi depleted allosteric SAMHD1 activators GTP and dGTP, thereby increasing active triphosphate metabolites in SAMHD1-proficient, but not SAMHD1-deficient, cells. Our findings suggest that the addition of IMPDHi to ara-C and F-ara-A may have therapeutic benefits in some AML cases.
Place, publisher, year, edition, pages
Taylor & Francis Group, 2025
Keywords
IMPDH, KMT2A, leukemia, SAMHD1, therapy resistance
National Category
Hematology Cancer and Oncology
Identifiers
urn:nbn:se:umu:diva-247986 (URN)10.1080/15384101.2025.2601796 (DOI)001640225100001 ()41399259 (PubMedID)2-s2.0-105024974208 (Scopus ID)
Funder
Swedish Society for Medical Research (SSMF), SG-23–0178-BSwedish Cancer Society, 24–0829-PTSwedish Cancer Society, 19–0056-JIASwedish Cancer Society, 23–2782-PjSwedish Cancer Society, 24 3398 PjSwedish Cancer Society, 25 3999 IA JCIASwedish Cancer Society, 22–2377-PjSwedish Childhood Cancer Foundation, TJ2022-0063Swedish Childhood Cancer Foundation, PR2022-0003Swedish Childhood Cancer Foundation, PR2023-0031Swedish Society of Medicine, SLS-998536Sjöberg Foundation, 2020–008Swedish Research Council, 2024–02941Swedish Research Council, 2022–00675Swedish Research Council, 2020–01902Karolinska Institute, 2021–00272
2025-12-292025-12-292025-12-29